Liquidia Co. (NASDAQ:LQDA) Insider Jason Adair Sells 1,189 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) insider Jason Adair sold 1,189 shares of the firm’s stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $17,335.62. Following the transaction, the insider now directly owns 111,537 shares in the company, valued at approximately $1,626,209.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jason Adair also recently made the following trade(s):

• On Monday, March 18th, Jason Adair sold 4,657 shares of Liquidia stock. The shares were sold at an average price of $15.81, for a total transaction of $73,627.17.

Liquidia Trading Down 1.9 %

LQDA stock opened at $13.68 on Tuesday. The firm has a 50 day moving average of $14.77 and a 200-day moving average of $10.88. Liquidia Co. has a 12-month low of $5.71 and a 12-month high of $16.99. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -11.40 and a beta of 0.16.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. The business had revenue of $4.53 million for the quarter, compared to analysts’ expectations of $5.29 million. Sell-side analysts forecast that Liquidia Co. will post -0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LQDA. Findell Capital Management LLC purchased a new position in shares of Liquidia during the 4th quarter worth approximately $25,095,000. State Street Corp increased its stake in shares of Liquidia by 861.0% during the 2nd quarter. State Street Corp now owns 1,448,211 shares of the company’s stock worth $6,314,000 after purchasing an additional 1,297,509 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Liquidia during the 4th quarter worth approximately $12,331,000. Kynam Capital Management LP increased its stake in shares of Liquidia by 34.9% during the 4th quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock worth $32,461,000 after purchasing an additional 698,324 shares in the last quarter. Finally, Beryl Capital Management LLC purchased a new position in shares of Liquidia during the 3rd quarter worth approximately $3,135,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on LQDA shares. Bank of America raised their price objective on shares of Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. Wedbush restated an “underperform” rating and issued a $3.00 price objective on shares of Liquidia in a research report on Thursday, December 21st. LADENBURG THALM/SH SH raised their price objective on shares of Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of Liquidia in a research report on Wednesday, April 10th. Finally, HC Wainwright raised their price objective on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).